Ars Pharmaceuticals Inc (SPRY) Return on Investment ROI from the second quarter of 2026 to second quarter of 2025 and for the year 2026, average high and low, overall ranking from Jun 30 2026 to Jun 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Ars Pharmaceuticals Inc   (NASDAQ: SPRY)


Ars Pharmaceuticals Inc's ROI from its second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Ars Pharmaceuticals Inc's ROI in the second quarter of 2026?
Ars Pharmaceuticals Inc recorded a cumulative net loss of $-215 million during 12 months ending in the second quarter of 2026, resulting in a negative return on investment (ROI) of -83.1%.

Within the Healthcare sector 361 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the first quarter of 2026 from 3271 to 3859.

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Investment Change TTM -5.4 % 6.96 % 21.72 % 39.77 % 20.83 %
Y / Y Net Income Change TTM - - - - -
Investment (TTM) in Millions 189 238 289 322 268
Return On Investment (TTM) -83.1 % -70.94 % -58.17 % -26.3 % -17.52 %
SPRY's Overall Ranking # 3859 # 3271 # 3427 # 3198 # 2944
Seq. Investment Change TTM -7.1 % -5.24 % -3.22 % 11.03 % 5.04 %
Seq. Net Income Change TTM - - - - -
Net Income (TTM) in Millions -215 -198 -171 -80 -48

SPRY Company Profile >> Back to SPRY Roi Comparisons >> See Annual SPRY Return On Investment



Return On Investment SPRY's Ranking
Within: No.
Industry # 149
Sector # 362
Overall # 3859

Return On Investment Statistics
High Average Low
3.31 %
-25.82 %
-83.1 %
(Dec 31 2024)   (Jun 30 2026)







Financial Statements
Ars Pharmaceuticals Inc's II. Quarter Investments $ 189 Millions SPRY's Balance sheet
Ars Pharmaceuticals Inc's II. Quarter Income $ -62 Millions Quarterly SPRY's Income Statement
SPRY's Income by Division See SPRY's Income by Division


SPRY Annual Return On Investment (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Investments in Millions 289 328 231 276 319
Y / Y Investment Growth -11.96 % 41.99 % -16.38 % -13.37 % -
Net Income in Millions -171 8 -54 -35 -89
Y / Y Net Income Growth - - - - -
Annual Return On Investment -59.37 % 2.44 % -23.56 % -12.57 % -28.09 %


Annual Roi Comment


Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
SPRY's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for SPRY's Competitors
Subscribers only: Roi for Ars Pharmaceuticals Inc's Suppliers
Subscribers only: Return On Investment for SPRY's Customers

Other Ratios
SPRY's Roa SPRY's Inventory Turnover Ratio SPRY's Growth Rates SPRY's Dividend Statistics
SPRY's Profitability Ratios SPRY's Asset Turnover Ratio SPRY's Dividend Growth
SPRY's Roe SPRY's Valuation Ratios SPRY's Financial Strength Ratios SPRY's Dividend Payout Ratio



Companies with similar Return On Investment at Jun 30 2026, within Healthcare Sector ROI

Date modified: 2026-09-03T12:16:46+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.